U.S. markets closed
  • S&P Futures

    4,407.50
    -14.25 (-0.32%)
     
  • Dow Futures

    34,309.00
    -153.00 (-0.44%)
     
  • Nasdaq Futures

    15,302.25
    -23.75 (-0.15%)
     
  • Russell 2000 Futures

    2,219.80
    -8.50 (-0.38%)
     
  • Crude Oil

    71.62
    -0.35 (-0.49%)
     
  • Gold

    1,752.40
    +1.00 (+0.06%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1726
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3714
    -0.0023 (-0.17%)
     
  • USD/JPY

    109.9830
    +0.0880 (+0.08%)
     
  • BTC-USD

    47,138.93
    -645.55 (-1.35%)
     
  • CMC Crypto 200

    1,178.46
    -47.07 (-3.84%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Inspire Medical Price Target Cut At Piper Sandler After Updated CMS Rates

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Piper Sandler has lowered Inspire Medical Systems Inc's (NYSE: INSP) price target to $235 (still an upside of around 30%) from $255 and keeps an Overweight rating.

  • The cut comes after the Centers for Medicare and Medicaid Services (CMS) issued its calendar year 2022 proposed physician fee schedule.

  • The document included proposed rates of physician reimbursement for the new Hypoglossal Nerve Stimulation (HGNS) codes, analyst Adam Maeder tells investors in a research note.

  • He says the primary HGNS code appears to reimburse physicians $870 for performing an Inspire procedure on a Medicare patient, which comes in well below expectations of around $1,500.

  • The final rule will be announced in November after a 60-day public comment period closing on September 13.

  • Price Action: INSP shares are down 5.37% at $177.62 during the market session on the last check Wednesday.

Latest Ratings for INSP

Jul 2021

Piper Sandler

Maintains

Overweight

Feb 2021

Piper Sandler

Maintains

Overweight

Feb 2021

SVB Leerink

Maintains

Outperform

View More Analyst Ratings for INSP
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.